Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study

Highlights • Dyspareunia, dryness and irritation/itching were evaluated. • Intravaginal prasterone (0.50%, 6.5 mg) was administered daily for 52 weeks. • All three moderate/severe (MS) symptoms respond in parallel to treatment. • The choice of one MS symptom as most bothersome does not affect the re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Maturitas 2015-05, Vol.81 (1), p.46-56
Hauptverfasser: Labrie, Fernand, Archer, David F, Bouchard, Céline, Girard, Ginette, Ayotte, Normand, Gallagher, John C, Cusan, Leonello, Baron, Mira, Blouin, François, Waldbaum, Arthur S, Koltun, William, Portman, David J, Côté, Isabelle, Lavoie, Lyne, Beauregard, Adam, Labrie, Claude, Martel, Céline, Balser, John, Moyneur, Érick
Format: Artikel
Sprache:eng
Schlagworte:
Administration, Intravaginal
Adult
Aged
Atrophy - complications
Atrophy - drug therapy
Dehydroepiandrosterone
Dehydroepiandrosterone - administration & dosage
Double-Blind Method
Dyspareunia - drug therapy
Dyspareunia - etiology
Female
Hormones - administration & dosage
Humans
Internal Medicine
Local action
Middle Aged
Obstetrics and Gynecology
Postmenopause
Prasterone
Pruritus - drug therapy
Secondary symptomatology
Severity of Illness Index
Sexual Behavior
Vagina - pathology
Vaginal Diseases - complications
Vaginal Diseases - drug therapy
Vulva - pathology
Vulvar Diseases - complications
Vulvar Diseases - drug therapy
Vulvovaginal atrophy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • Dyspareunia, dryness and irritation/itching were evaluated. • Intravaginal prasterone (0.50%, 6.5 mg) was administered daily for 52 weeks. • All three moderate/severe (MS) symptoms respond in parallel to treatment. • The choice of one MS symptom as most bothersome does not affect the response.
ISSN:0378-5122
1873-4111
DOI:10.1016/j.maturitas.2015.02.005